A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India인도의 코비드 전용 병원(DCH)에서 COVID-19 질병 관리를 위한 보조 요법으로서 Ayurcov(AyurCoro3)의 역할을 연구하기 위한 무작위, 통제, 맹검, 병렬 그룹 임상 시험Randomized Controlled Trial Published on 2022-08-012022-09-11 Journal: Complementary therapies in medicine [Category] SARS, 임상, 치료제, [키워드] adjuvant adverse events alternative medicine alum Antiviral Ayurcov Ayurveda blinded CAM carried Chain Reaction clinical trial complementary Complementary and alternative medicine. control group Controlled trial COVID-19 COVID-19 disease COVID-19 infections Ct values Curcuma Day diagnosed discharge disease dose evaluate Formulation functional Functional status higher risk India ingredient Limited management Mild mild to moderate Mild-to-moderate milk moderate outcome parallel group Patient polymerase chain polymerase chain reaction proportion Randomized real time receiving recruited reduction in regimen resolution of symptom reverse transcriptase Reverse transcriptase polymerase chain reaction Rock Candy rRT-PCR severe COVID-19 disease Severe COVID-19 Infection severe symptoms severity significantly significantly lower significantly more Sita Standard of care Symptom symptom resolution therapeutic effect therapeutic options therapy for COVID-19 transcriptase Treatment Urine [DOI] 10.1016/j.ctim.2022.102824 PMC 바로가기 [Article Type] Randomized Controlled Trial
COVID-19 patient with B Cell Lymphoma co-morbidity managed with co-administration of Ayurvedic formulationCase report Published on 2022-07-012022-10-05 Journal: Journal of Ayurveda and Integrative Medicine [Category] 진단, 치료제, [키워드] Achyranthe Ageusia Aloe Anti-viral antipyretics Antiviral approach Ayurveda Cancer chemotherapy cycle chronic co-morbidity condition COVID-19 COVID-19 pandemic COVID-19 patient Diagnosis Eclipta Efficacy Embelia Fever First wave glycyrrhiza home quarantine Host immune response host response Immunocompromised immunocompromised status immunomodulatory In vitro studies infective Intervention Kidney disease lymphoma malaise male modulate oxygen saturation Patient positive regimen remained replicated respiratory complication RT-PCR supported took place treat treated Vitamin was done [DOI] 10.1016/j.jaim.2022.100632 [Article Type] Case report
Impact of AYUSH 64 as an adjunctive to standard of care in mild COVID 19 – An open-label randomized controlled pilot studyShort communication Published on 2022-07-012022-10-05 Journal: Journal of Ayurveda and Integrative Medicine [Category] 신약개발, [키워드] adverse events all-cause mortality approach asymptomatic patient Ayurveda AYUSH 64 baseline benefit Clinical improvement conducted control group COVID 19 COVID-19 patient COVID19 COVID19 patients death Disease progression dose Effect Efficacy and safety evaluate group groups Impact incidence Inconclusive Indian traditional system of medicine invasive malaria material mechanical ventilator Mild Mortality Open-label outcome outcomes Oxygen therapy patients per day pilot study proportion Randomized reduction in Result SARS-CoV-2 Standard of care statistically significant difference Symptom symptom duration symptomatic treat ventilator was reduced WHO ordinal scale [DOI] 10.1016/j.jaim.2022.100587 [Article Type] Short communication
AYUSH-64 as an adjunct to standard care in mild to moderate COVID-19: An open-label randomized controlled trial in Chandigarh, IndiaRandomized Controlled Trial Published on 2022-06-012022-10-04 Journal: Complementary therapies in medicine [Category] COVID19(2023년), SARS, 신약개발, 임상, [키워드] Adverse Analysis Ayurveda Care Chest clinical recovery conducted contributed control group COVID COVID-19 determine diagnosed disease double-blind drug effective Efficacy Final HRCT incidence India integrative medicine less metabolic functions Mild moderate Moderate COVID-19 negative RT-PCR Open-label outcome pandemic parallel-group participant Participants Patient pro-inflammatory proportion Proportion of participant Randomized Randomized controlled trial reaction reported Safe Significant significantly standard care Tablet therapeutic efficacy Trial trials two groups viral disease [DOI] 10.1016/j.ctim.2022.102814 PMC 바로가기 [Article Type] Randomized Controlled Trial
Efficacy and safety of AYUSH-64 as standalone or adjunct to standard care in COVID-19: a structured summary of protocol for a systematic reviewArticle Published on 2022-05-242023-07-09 Journal: Systematic Reviews [Category] COVID19(2023년), [키워드] Ayurveda AYUSH-64 pandemic Polyherbal SARS-CoV-2 [DOI] 10.1186/s13643-022-01983-8 PMC 바로가기
Efficacy of add-on Ayurveda and Yoga intervention in health care workers of tertiary care hospital during COVID-19: Randomized controlled trialControlled Trial Published on 2022-05-082023-06-16 Journal: Complementary therapies in clinical practice [Category] COVID19(2023년), MERS, SARS, [키워드] Anxiety Ayurveda complementary therapy COVID-19 RCT yoga [DOI] 10.1016/j.ctcp.2022.101601 PMC 바로가기 [Article Type] Controlled Trial
Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary Outcomes of Randomized controlled trialShort communication Published on 2022-05-012022-10-05 Journal: Journal of Ayurveda and Integrative Medicine [Category] 신약개발, 임상, [키워드] Ayurveda BNP breathlessness clinical trial coagulative complement Complication control group Controlled trial cough COVID-19 COVID-19 disease creatinine phosphokinase CRP disease Diseases fatigue Hospital stay ICU infective Inflammatory marker integrative medicine intervention group Madhav Rasayan plus management marker Moderate COVID-19 organ outcome parallel group patients patients with moderate Pro Quality of life Randomized controlled trial reduced restored reveal severity significantly standard care statistically significant reduction supplemental oxygen symptoms of COVID-19 Tablet tissue Treatment was reduced [DOI] 10.1016/j.jaim.2022.100590 [Article Type] Short communication
Ayurveda co-interventions have supported complete recovery in severe COVID-19 infection with a chest severity score 18/25: A case reportCase report Published on 2022-04-012022-10-05 Journal: Journal of Ayurveda and Integrative Medicine [Category] 바이오마커, 신약개발, [키워드] addition Ayurveda biochemical Biomarker Care Case report Chest Chest severity score clinical recovery Complete complete recovery complications COVID COVID-19 COVID-19 infection CRP CT scan Deterioration evaluated high mortality hospital hypoxia ICU care IL-6 Improvements Initially Integrative care Intervention management outcome outcomes oxygen support predicted Predictive predictor presenting Prevent Prognosis Rapid reported score severe COVID-19 Severe COVID-19 Infection severity supported the patient treated [DOI] 10.1016/j.jaim.2021.02.008 [Article Type] Case report
Repurposing Siddha mercurial drug for mild to moderate COVID-19 – Case series and exploration of its chemical profileCase report Published on 2022-04-012022-10-05 Journal: Journal of Ayurveda and Integrative Medicine [Category] 신약개발, [키워드] 1H-Imidazole 9,12-Octadecadienoic acid acute respiratory syndrome age Ayurveda body temperature Chemical profile Chest compounds coronavirus cough COVID-19 COVID-19 patients Drug discovery female Fever first dose Gas Chromatography-Mass Spectrometry home quarantine infected patient Inflammatory diseases kidney liver Liver function loss of taste male Mercury Mild moderate Moderate COVID-19 normalized oxygen saturation Pain parameter plasma positive renal function renal impairment repeated repurposing required Research RT-PCR Safe SARS-CoV-2 Siddha Side-effect Swab Symptom therapy Traditional medicine treat treated Treatment Vajra was done were assessed X-ray/CT [DOI] 10.1016/j.jaim.2021.06.009 [Article Type] Case report
Antiviral activity of traditional medicinal plants from Ayurveda against SARS-CoV-2 infectionSARS-CoV-2 감염에 대한 아유르베다 전통 약용 식물의 항바이러스 활성Article Published on 2022-03-012022-09-11 Journal: Journal of biomolecular structure & dynamics [Category] SARS, 치료제, [키워드] ACE2 ACE2 receptor amarogentin Analysis angiotensin Antiviral antiviral activity antiviral role apoptotic pathway approach attachment inhibitor Ayurveda belladonnine COVID-19 criteria demonstrated disease drug design drug-likeness drug-target interaction Drug-target interactions Efficacy etiological agent G-protein gene network gene network analysis highest affinity Host membrane protein MOST Necrosis network analysis nuclear parameter pathway Pathways pharmacokinetic pharmacokinetics Phosphorylation plant positive potential therapy predicted Protein protein kinase Protein kinase B receptor Regulation responsible SARS-CoV-2 SARS-COV-2 infection secretion Serine Signaling spike glycoprotein Structure-based drug design suggested target target prediction. Toxicity Transport Tumor tumor necrosis tumor necrosis factor Vaccine was performed [DOI] 10.1080/07391102.2020.1832577 PMC 바로가기 [Article Type] Article